超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

荷蘭Agendia 
Agendia是開發基于基因表達分析的診斷工具的全球領導企業。公司關注使用腫瘤基因表達分析的診斷化驗工具的開發與商業化。Agendia率先對于預后檢驗——MammaPrint?——進行了商業化，從而能夠預測乳腺癌重發的機率。Agendia的產品線最近又新增了發現未知癌瘤的CupPrint?檢驗。Agendia與荷蘭癌癥研究院(NKI)保持著密切聯系，從而能夠接觸到癌癥研究的最新發展。在開發出了新型癌癥診斷技術之后，Agendia將會發揮它的專家技術，為那些關注治癌新藥開發的企業尋找想要的新基因表達式。

In 2008, Agendia launches its diagnostic test TargetPrint for breast cancer patients, which allows to obtain highly reliable quantitative data about each patients breast tumor and adds a secure prognostic tool for future treatment.

Leveraging the benefits of gene expression profiling
- microarray technology – and collaboration
The leaders of Agendia are the inventors and initiators of diagnostic microarray testing - the technology which forms the basis for the company’s commercially available tests.
Clinically-relevant tumor gene expression profiles are established through in-house research, research collaborations and strategic alliances with leading academic institutes. In particular, Agendia has very close links, both geographically and collaboratively, with The Netherlands Cancer Institute.

Once validated, these profiles are used to develop commercially available tests utilizing the microarray technology. Tests are currently performed in a high quality clinical laboratory at the company’s headquarters in Amsterdam, The Netherlands.

A growing business
Agendia working to develop further tests and applications and to market the current test portfolio globally through direct sales and an expanding distribution network. Both MammaPrint and CupPrint* are CE-marked and the company is ISO 17025 and CLIA accredited.
*